Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**2-Iodomelatonin** is a synthetic analog of melatonin, structurally characterized as an iodinated derivative of the natural hormone. It acts as a potent and selective agonist at melatonin receptors, particularly showing high affinity for the melatonin receptor type 1 (MT1), with approximately fivefold selectivity over the MT2 subtype. Its primary use is experimental, serving as a radioligand or pharmacological tool to study melatonergic signaling pathways and receptor pharmacology in vitro and in vivo. It has not been approved for therapeutic use in humans[9]. Mechanistically, it inhibits forskolin-stimulated cAMP production via activation of MT1 receptors much more potently than endogenous melatonin[9].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 2-iodomelatonin.